Mark J. Foley - 13 Oct 2022 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: CEO, Director
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 13 Oct 2022
Net transactions value: -$1,328,920
Form type: 4
Filing time: 14 Oct 2022, 19:02:33 UTC
Previous filing: 09 Mar 2023
Next filing: 03 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	$1,328,920	-49,274	-6.4%	$26.97	717,487	13 Oct 2022	Direct	F1
holding	RVNC	Common Stock						110,913	13 Oct 2022	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock awards ("RSA's") for 400,000 shares. The RSA's vest in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
F2	These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.

Content

Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock awards ("RSA's") for 400,000 shares. The RSA's vest in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.

These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.